brand logo

Am Fam Physician. 2005;72(8):1613-1614

Delays in influenza vaccine distribution or vaccine supply shortages have occurred in the United States in three of the past five influenza seasons. In previous years, prioritization was implemented to ensure the availability of vaccine for persons at the highest risk of complications from influenza. The Centers for Disease Control and Prevention (CDC) has released updated recommendations for priority use of trivalent inactivated influenza vaccine (TIV) during the 2005–2006 influenza season. Additional information is available online athttp://www.cdc.gov/flu.

Four manufacturers are expected to provide influenza vaccine during the 2005–2006 influenza season (see accompanying table). Because of uncertainties about the number of available vaccine doses and the timing of distribution, the CDC recommends that the following groups be given priority to receive TIV until October 24, 2005:

• Persons 65 years and older with or without comorbid conditions

• Persons two to 64 years of age with comorbid conditions

• Children six to 23 months of age

• Residents of long-term care facilities

• Pregnant women

• Health care professionals who provide direct patient care

• Household contacts and out-of-home caregivers of children younger than six months

Starting October 24, 2005 all persons will be eligible for vaccination

The tiered use of prioritization is not recommended for LAIV administration. LAIV may be administered at any time for vaccination of nonpregnant healthy persons five to 49 years of age, including most health care professionals and other persons in close contact with groups at high risk for influenza-related complications.

ManufacturerVaccineFormulationContains thimerosal?Age indicationProjected doses
Sanofi Pasteur, Inc.Fluzone TIVMultidose vialYes6 months and older60 million*
Single-dose prefilled 0.5-mL syringe or vialNo3 years and older
Single-dose prefilled 0.25-mL syringeNo6 to 35 months
Chiron Corp.Fluvirin TIVMultidose vialYes4 years and older18 to 26 Million †
Single-dose prefilled 0.5-mL syringeNo ‡4 years and older
GlaxoSmithKline, Inc.Fluarix TIVSingle-dose prefilled 0.5-mL syringeNo ‡18 years and older8 million
MedImmune Vaccines, Inc.FluMist LAIVSingle-dose nasal sprayerNoHealthy, nonpregnant persons 5 to 49 years of age3 million

Continue Reading


More in AFP

Copyright © 2005 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See https://www.aafp.org/about/this-site/permissions.html for copyright questions and/or permission requests.